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Abstract 
Background: The present randomized clinical trial characterized the beneficial effects of a multi‑strain probiotics 
supplementation on improving circulating endotoxin levels (primary endpoint) and other cardiometabolic biomark‑
ers (secondary endpoint) in patients with T2DM.
Methods: A total of 78 adult Saudi T2DM patients (naïve and without co‑morbidities) participated in this clinical 
trial and were randomized to receive twice daily placebo or probiotics [(2.5 × 109 cfu/g) containing the following 
bacterial strains: Bifidobacterium bifidum W23, Bifidobacterium lactis W52, Lactobacillus acidophilus W37, Lactobacil-
lus brevis W63, Lactobacillus casei W56, Lactobacillus salivarius W24, Lactococcus lactis W19 and Lactococcus lactis W58 
 (Ecologic®Barrier)] in a double‑blind manner for 12 weeks. Anthropometrics and cardiometabolic profiles were 
obtained at baseline and after 12/13 weeks of treatment.
Results: After 12/13 weeks of intervention and using intention‑to‑treat analysis, no difference was noted in endo‑
toxin levels between groups [Placebo − 9.5% vs. Probiotics − 52.2%; (CI − 0.05 to 0.36; p = 0.15)]. Compared with 
the placebo group however, participants in the probiotics groups had a significant but modest improvement in WHR 
[Placebo 0.0% vs. Probiotics 1.11%; (CI − 0.12 to − 0.01; p = 0.02)] as well as a clinically significant improvement in 
HOMA‑IR [Placebo − 12.2% vs. Probiotics − 60.4%; (CI − 0.34 to − 0.01; p = 0.04)].
Conclusion: Using a multi‑strain probiotic supplement daily for 12/13 weeks significantly improved HOMA‑IR and 
modestly reduced abdominal adiposity among medication naïve T2DM patients.
Trial Registration: ClinicalTrials.gov Identifier: NCT01765517, Registered January 10, 2013
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Background
In the last few years the gut microbiome has gained 
considerable interest due to its ability to coexist with its 
human host and complement several key physiologic 
processes peacefully maintaining homeostasis and over-
all human health [1]. One of the accepted theories that 
explain the contribution of gut microbes in the develop-
ment of diseases is sub-chronic inflammation second-
ary to endotoxemia. This state occurs when fragments of 
gut-derived Gram negative bacteria (lipopolysaccharides 
or endotoxin) traverse the intestinal mucosa to enter the 
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circulation, and may represent an important mediator of 
low-grade systemic inflammation influenced by the host’s 
own gut microbiota and metabolic state [2]. Previous 
studies have also shown that endotoxin can stimulate an 
innate immune response from adipose, liver and skeletal 
muscle tissues, leading to increased production of pro-
inflammatory cytokines [3].
There has been accumulating evidence pointing to the 
manipulation of the gut microbiome in the prevention 
and reversal of several chronic non-communicable dis-
eases such as obesity, type 2 diabetes mellitus (T2DM) 
and the metabolic syndrome [4]. It is now established 
that dietary intake and nutrition management are sig-
nificant and effective external factors in modifying the 
gut ecosystem [5]. Specifically, probiotics, or live bac-
teria naturally found in the human body that confer 
health benefits, have shown great potential as adjuvant 
therapies for a number of insulin-resistant diseases. 
Currently, randomized clinical trials are limited to 
strengthen this case. The present investigation aims to 
fill this gap.
In this study, we determine whether a 12/13 week sup-
plementation of a multi-strain probiotic would induce 
favorable changes in circulating endotoxin levels (pri-
mary outcome) and cardiometabolic profile (secondary 
outcome) of medication naïve T2DM individuals.
Methods
The present study is a 12-week single-center, double-
blind, randomized, placebo-controlled study. The proto-
col has been published previously [6] and was registered 
at the US National Institute of Health (ClinicalTrials.gov 
Identifier: NCT01765517). Ethical approval was obtained 
from the Ethics Committee in the College of Science 
(Approval Code 8/25/16519), King Saud University in 
Riyadh, Saudi Arabia and written informed consents 
were obtained from all participants prior to inclusion.
Subjects
All participants were recruited in the outpatient depart-
ment of King Salman Hospital, Riyadh, Saudi Arabia. 
A total of 150 adult Saudis (aged 30–60  years old) with 
newly diagnosed T2DM were initially invited to partici-
pate. Participants with T2DM complications and unsta-
ble glycemic control were excluded. Those who were 
already taking probiotics as well as antibiotics, 6  weeks 
before inclusion, women lactating or pregnant, par-
ticipants who would anticipate changes in antidiabetic 
medications (if any) in the next 6 months, on insulin or 
its analogues and those with gastrointestinal diseases, 
such as irritable bowel syndrome, were excluded. Thirty 
participants failed to meet the inclusion criteria and 24 
refused to participate. A total of 96 participants were 
eligible and gave informed consent. They were randomly 
assigned to either placebo or probiotic sachets unknown 
to both the principal investigator and the participants. 
Seventy-eight participants were able to complete the 
12 week intervention. A flowchart is shown in Fig. 1.
Probiotic supplements and allocation
All eligible and consenting participants were given a 
unique code as identifier. They were allocated (1:1) to 
receive either probiotics or placebo. The randomiza-
tion scheme was computer generated by Winclove 
using permuted blocks with block size equal to 4. It was 
impossible for research personnel involved with partici-
pants to adjust randomization or discern what product 
participants were receiving, ensuring true allocation 
concealment. The probiotic group received sachets 
with 2  g freeze-dried powder of the probiotic mixture 
 Ecologic®Barrier (Winclove probiotics, the Netherlands). 
 Ecologic®Barrier (2.5  ×  109  cfu/g) contains the follow-
ing bacterial strains: Bifidobacterium bifidum W23, Bifi-
dobacterium lactis W52, Lactobacillus acidophilus W37, 
Lactobacillus brevis W63, Lactobacillus casei W56, Lac-
tobacillus salivarius W24, Lactococcus lactis W19 and 
Lactococcus lactis W58. The placebo group received the 
same sachets consisting of the carrier of the probiotic 
product that is maize starch and maltodextrins. The pla-
cebo is indistinguishable in color, smell and taste from 
the probiotic sachets. All participants were asked to con-
sume two sachets per day (dissolving contents in glass of 
water) once before breakfast and before going to bed.
Monitoring and blood sample collection
Anthropometry include height (cm), weight (kg), blood 
pressure (mmHg) waist and hip measurements (cm) were 
done at baseline and after 12 weeks of intervention. Fast-
ing blood samples were also collected at baseline and 
after 12  weeks. Samples were immediately centrifuged 
and serum samples separated. All samples were put in 
ice and immediately delivered to Prince Mutaib Chair 
for Biomarkers of Osteoporosis in King Saud University 
for storage at – 20 °C until further analysis. Participants 
were asked to return every 4 weeks to surrender unused 
sachets and to be given fresh refill to monitor compli-
ance. Participants were also asked for any side effects.
Biochemical analyses
Fasting serum samples were analyzed for glucose and 
lipid profile (total cholesterol, HDL-cholesterol and tri-
glycerides) using routine analyzer (Konelab, Espoo, 
Finland). LDL-cholesterol was calculated using the 
Friedwald equation. Serum insulin and c-peptide were 
measured using electrochemiluminescence assay (Roche 
Diagnostics, Germany). Endotoxin was measured using a 
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limulus amebocyte lysate (LAL) quantitative kinetic assay 
(Lonza, MD, USA). A spike recovery was performed 
using a sample dilution of 1:40. The recovery spike was 
60% and was within the acceptable range of 50–200%. 
All serum samples were analyzed at baseline and after 
12 weeks of intervention.
Data analysis
Sample size calculation was previously done using endo-
toxin as primary endpoint [6] and repeated after obtain-
ing actual results. The sample size in the present study 
(N = 39 per group) has an actual power of 83%. Statistical 
analysis was performed using Intention-to-treat (ITT) 
analysis, where missing data were dealt by using the last 
observation carried forward (LOCF) method. Per-pro-
tocol (PPA) analysis was also performed on participants 
who successfully completed the trial and is presented 
as a additional data (Additional file  1: Table  S1). Data 
were analyzed using SPSS (version 16.5 Chicago, IL, 
USA). Mean and standard deviations were used to rep-
resent the data for the normal variables, while median 
and interquartile range were used to report non-normal 
variables. Furthermore, frequencies and percentages (%) 
were reported for the categorical data. Changes were 
Fig. 1 Consort flowchart
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also calculated as mean and as percentage. Correlations 
between endotoxin anthropometrics, glycemic and lipid 
profile were measured using Spearman correlation coef-
ficient. Independent sample Student T-test and Mann–
Whitney U test was used to determine the significant 
difference between placebo and probiotic groups at base-
line. Mixed method analysis of covariance (ANCOVA) 
was used to determine within and between group differ-
ences after adjusting for baseline observations and covar-
iates including WHR, MAP, Glucose (mmol/l), TC/HDL 
and Endotoxin (IU/ml). All non-normal variables were 
transformed prior to parametric testing. Intervention 
effects were presented at 95% confidence interval (CI). 
p < 0.05 was considered statistically significant.
Results
Table  1 shows the demographic characteristics of par-
ticipants assigned to placebo (N  =  39) and probiot-
ics (N =  39). No differences were found in age, weight, 
BMI and sex distribution. The placebo group had signifi-
cantly higher waist-hip ratio than the probiotics group 
(p = 0.02). The probiotics group on the other hand, had 
significantly higher diastolic and mean arterial blood 
pressure (p values 0.04 and 0.024), respectively. With 
regards to glycemic and lipid parameters, the probiotics 
group had significantly higher median glucose levels, as 
well as circulating levels of total cholesterol and LDL-
cholesterol than the placebo group (p < 0.001, 0.001 and 
0.05, respectively). The rest of the parameters were not 
significantly different from one another.
Endotoxin
Within and between group effects of participant charac-
teristics are shown in Table  2. No difference was noted 
in endotoxin levels between groups [Placebo −  9.5% 
vs. Probiotics −  52.2%; (CI −  0.05 to 0.36; p  =  0.15)]. 
Within group comparisons however showed a signifi-
cant decrease in endotoxin levels in the probiotics group 
(p  <  0.01). This was not observed in the placebo group. 
Mean differences between placebo and probiotics group 
are presented in Fig. 2.
Anthropometric and clinical measures
Compared with the placebo group, participants in the 
probiotics groups had a significant improvement in WHR 
[Placebo 0.0% vs. Probiotics 1.11%; (CI − 0.12 to − 0.01; 
p = 0.02)]. This significant reduction was also observed 
using PPA [Placebo 0.0% vs. Probiotics 1.11%; (CI − 0.14 
to − 0.03; p = 0.01)] (Additional file 1: Table S1). No dif-
ferences were noted in weight [Placebo 0.5% vs. Probiot-
ics −  1.4%; (CI −  17.1 to 1.1; p =  0.08)], BMI [Placebo 
0.5% vs. Probiotics − 0.4%; (CI − 4.92 to 2.39; p = 0.49)], 
systolic blood pressure [Placebo 0.3% vs. Probiotics 
−  0.4%; (CI −  5.18 to 10.06; p =  0.52)], diastolic blood 
pressure [Placebo 1.5% vs. Probiotics − 4.5%; (CI − 5.82 
to 6.58; p = 0.90)] and MAP [Placebo 1.0% vs. Probiotics 
− 4.4%; (CI − 4.58 to 6.72; p = 0.71)]. Within group com-
parisons showed a significant decrease in systolic and 
diastolic as well as mean arterial blood pressure in the 
probiotics group (p < 0.01, 0.03 and < 0.01, respectively) 
post intervention. These differences were not observed in 
the placebo group. Furthermore, no significant changes 
in weight, BMI and WHR were observed in either group 
after 3 months (Table 2).
Glycemic profile
A clinically significant improvement in HOMA-IR was 
observed in the probiotics group compared to placebo 
[Placebo −  12.2% vs. Probiotics −  60.4%; (CI −  0.34 to 
− 0.01; p = 0.04)]. No differences were observed in glu-
cose [Placebo 14.3% vs. Probiotics −  27.4%; (CI −  0.06 
to 0.16; p = 0.36)], insulin [Placebo − 18.3% vs. Probiot-
ics −  30.3%; (CI −  0.24 to 0.07; p =  0.29)] and C-pep-
tide [Placebo 0.0% vs. Probiotics 80.0%; (CI −  0.38 to 
0.53; p  =  0.74)]. Within group comparisons revealed 
significantly higher glucose levels in the placebo group 
after 3  months intervention (p  =  0.02). In contrast, 
Table 1 Baseline parameters according to placebo 
and probiotics
Data presented as Mean ± SD for normal variables while non-normal variables 
are presented as Median (inter-quartile range)
Parameters Placebo (N = 39) Probiotics (N = 39) p
Males (%) 21 (56.8) 19 (51.4)
Age (years) 46.6 ± 5.9 48.0 ± 8.3 0.396
Weight (kg) 79.5 ± 15.7 75.6 ± 11.0 0.221
BMI (kg/m2) 30.1 ± 5.0 29.4 ± 5.2 0.588
Waist‑hip ratio 1.0 ± 0.1 0.9 ± 0.1 0.020
Systolic BP (mmHg) 129.5 ± 10.3 134.8 ± 14.6 0.072
Diastolic BP (mmHg) 78.6 ± 8.6 83.6 ± 11.8 0.040
Mean arterial pres‑
sure (MAP)
95.5 ± 7.7 100.7 ± 11.1 0.024
Glucose (mmol/l) 7.0 (5.7 to 11.2) 11.7 (8.4 to 16.4) < 0.001
Insulin (uU/mL) 13.1 (7.7 to 18.7) 9.9 (7.7 to 16.4) 0.484
C‑peptide (ng/ml) 0.1 (0.1 to 0.5) 0.4 (0.0 to 1.8) 0.221
HOMA‑IR 4.1 (2.3 to 7.3) 5.3 (3.5 to 10.2) 0.096
Triglycerides 
(mmol/l)
2.2 ± 1.4 2.5 ± 1.4 0.358
Total cholesterol 
(mmol/l)
5.2 ± 1.0 5.8 ± 1.3 0.044
HDL‑cholesterol 
(mmol/l)
1.1 ± 0.3 1.0 ± 0.3 0.078
LDL‑cholesterol 
(mmol/l)
3.1 ± 0.9 3.7 ± 1.3 0.051
Total‑cholesterol/
HDL ratio
5.0 ± 1.3 6.4 ± 2.2 0.001
Endotoxin (IU/ml) 2.1 (1.2 to 4.4) 4.6 (2.4 to 9.9) 0.002
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post-intervention levels of glucose, insulin, C-peptide 
and insulin resistance were significantly lower than 
baseline in the probiotics group (p  <  0.01,  <  0.01, 0.01 
and < 0.01, respectively).
Lipid profile
No differences were observed in all lipid indices: triglyc-
erides [Placebo − 9.1% vs. Probiotics − 31.2%; (CI − 0.96 
to 0.28; p  =  0.27)], total cholesterol [Placebo −  10.2% 
vs. Probiotics −  10.9%; (CI −  0.52 to 0.75; p  =  0.72)], 
HDL-cholesterol [Placebo − 6.4% vs. Probiotics − 14.0%; 
(CI −  0.22 to 0.14; p  =  0.65)], LDL-cholesterol [Pla-
cebo − 11.9% vs. Probiotics − 11.4%; (CI − 0.43 to 0.79; 
p = 0.55)] and total/hdl cholesterol ratio [Placebo − 2.2% 
vs. Probiotics −  16.7%; (CI −  0.72 to 2.38; p  =  0.29)]. 
Within group comparisons showed that both placebo and 
probiotics group had significantly lower levels of total 
cholesterol after intervention (p < 0.01). Only the probi-
otics group, however, showed significantly lower circulat-
ing triglycerides and LDL-cholesterol after intervention 
(p values 0.04 and 0.02, respectively). Both groups had 
no significant changes in the total/HDL cholesterol ratios 
post-intervention.
Table  3 shows the bivariate associations between 
endotoxin and parameters measured. In all participants, 
endotoxin was significantly associated with diastolic BP 
(R = 0.27; p = 0.03) and MAP (r = 0.26; p = 0.04). HDL-
cholesterol was inversely and significantly associated with 
endotoxin levels in all participants (R = − 0.25; p = 0.04) 
and in the probiotics group (R = − 0.35; p = 0.05). In the 
probiotics group, there were also significant associations 
between endotoxin and triglycerides (R = 0.37; p = 0.04) 
and total/HDL cholesterol ratio (R = 0.42; p = 0.02). The 
latter was also significant in all participants (R  =  0.32; 
p = 0.01).
Lastly, none of the participants complained of any seri-
ous side effects from the clinical trial. The most common 
complaint were minor gastrointestinal discomfort (feel-
ing bloated and increased flatulence during the first week 
of treatment) (N = 5, 1 in the placebo group and 4 in the 
probiotics group) which is common for first time probi-
otics users. This symptom gradually faded during the first 
weeks of treatment.
Discussion
Individuals with T2DM and those with insulin-resistance 
in general exhibit higher metabolic endotoxemia than 
their non-diabetic counterparts [7]. In animal studies it 
was demonstrated that increased levels of circulating 
insulin alters intestinal permeability, allowing gut endo-
toxins to leak in the circulation, which, in turn, initiates a 
cascade of inflammatory reactions via the innate immune 
pathway, thus explaining the subclinical inflammation in 
obesity and insulin-resistant states [8]. Furthermore, a 
widely accepted theory is that probiotics supplementa-
tion can restore a weakened intestinal barrier, prevent-
ing endotoxin influx in the circulation and ultimately 
reducing subclinical inflammation [9]. By manipulating 
endotoxin levels through the introduction of probiot-
ics in the digestive tract, it is believed that many endo-
toxin-induced metabolic disorders can be reversed, if 
not controlled. We conducted our 3-month randomized, 
double-blind, placebo-controlled clinical trial on the 
endotoxin-lowering effects of an 8-strain probiotics sup-
plement among participants with T2DM. We found that 
while circulating endotoxin levels in the probiotics group 
were no different than placebo after 3  months of inter-
vention, significant improvements in WHR and HOMA-
IR were observed.
A recent meta-analysis of RCTs done thus far on pro-
biotics and T2DM revealed that multiple species of 
Fig. 2 Mean differences in endotoxin levels in placebo versus probiotics using a intention‑to‑treat and b per protocol analysis
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probiotics and interventions longer than 8  weeks had 
stronger metabolic improvements in terms of improved 
glucose control and lipid profiles [10]. With 8-strains of 
probiotics supplements used over 3  month duration, 
we confirm these beneficial effects in reducing abdomi-
nal adiposity (measured as WHR) and insulin resistance 
(HOMA-IR). The lack of improvement in lipid profile 
however and other indices assessed in the present study 
do not supersede previous findings. Our results are in 
agreement with a recent double-blind, randomized trial 
involving 43 participants (Placebo N = 22 and Probiotic 
mix N =  21) who were given 8  weeks supplementation 
of probiotic mix (Lactobacillus acidophilus and casei; 
Lactococcus lactis; Bifidobacterium bifidum and lac-
tis; 2 × 1010 cfu/day) and found significant reduction in 
abdominal adiposity with no concomitant decrease in 
endotoxin levels [11]. Three probiotic species used in the 
former and the present study, namely, Bifidobacterium 
bifidum, Lactobacillus acidophilus and Lactobacillus 
casei, have been demonstrated to significantly improve 
glycemic, inflammatory and lipid profiles of patients with 
gestational diabetes mellitus after 6 weeks of supplemen-
tation [12, 13]. Lactococcus lactis, another potent probi-
otic species used in our study, was recently reported to 
cure diabetes in non-obese diabetic mice, in combina-
tion with low-dose anti-CD3, through a series of actions 
including decline in insulin autoantibody positivity and 
stable reversal of hyperglycemia [14]. Lactobacillus sali-
varius was also shown to reverse diabetes-induced intes-
tinal defense impairment through reversal of enteric 
dysbiosis and decreased endotoxin levels in streptozo-
tocin-induced diabetic mice [15]. Studies using Lactoba-
cillus salivarius as a stand-alone probiotic supplement for 
4–6 weeks in women with gestational diabetes, however, 
was not associated with any improvement in metabolic 
health and pregnancy outcome [16]. In this study, most 
likely, the cumulative potency of the 8 species employed 
may have contributed to the significant improvements 
in the HOMA-IR and WHR of the probiotics group. A 
recent randomized clinical trial involving 136 Malaysians 
with T2DM supplemented with either placebo or probi-
otics (Bifidobacterium and Lactobacillus) for 12  weeks 
also showed improvement in terms of glycemic control 
[17].
We were not able to elicit significant changes in BMI 
and body weight in both groups studied. This confirms 
several studies, including the recent meta-analysis by 
Park and Bae, who concluded limited efficacy of probiot-
ics in weight management [18]. However, clinical trials 
overall are still very limited and therefore current evi-
dence on probiotics, as weight loss agents are at most, 
suggestive. We also found no significant improvements in 
blood pressure although a recent study in animal mod-
els showed remarkable improvements in blood pressure 
Table 3 Baseline correlations between endotoxin and various parameters
Data presented as Spearman Correlation coefficients
Italic values indicate significance at p < 0.05
Parameters ALL (N = 78) Placebo (N = 39) Probiotics (N = 39)
R p R p R p
Age (years) − 0.06 0.64 − 0.13 0.48 − 0.16 0.40
Weight (kg) − 0.11 0.38 0.00 0.99 − 0.03 0.86
BMI (kg/m2) − 0.09 0.48 − 0.02 0.91 − 0.06 0.78
Waist‑hip ratio − 0.15 0.27 0.01 0.98 0.03 0.89
Systolic BP (mmHg) 0.25 0.05 0.16 0.40 0.21 0.28
Diastolic BP (mmHg) 0.27 0.03 0.25 0.19 0.10 0.59
Mean arterial pressure (MAP) 0.26 0.04 0.22 0.23 0.09 0.63
Glycemic profile
 Glucose (mmol/l) 0.22 0.08 0.15 0.44 − 0.01 0.96
 Insulin (uU/ml) − 0.12 0.35 − 0.18 0.35 − 0.10 0.59
 C‑peptide (ng/ml) 0.05 0.67 − 0.21 0.27 − 0.04 0.84
 HOMA‑IR 0.01 0.92 − 0.11 0.56 − 0.11 0.57
Lipid profile
 Triglycerides (mmol/l) 0.21 0.09 − 0.02 0.92 0.37 0.04
 Total cholesterol (mmol/l) 0.19 0.14 0.09 0.64 0.28 0.13
 HDL‑cholesterol (mmol/l) − 0.25 0.04 0.09 0.63 − 0.35 0.05
 LDL‑cholesterol (mmol/l) 0.14 0.27 − 0.03 0.88 0.23 0.22
 Total/HDL cholesterol ratio 0.32 0.01 0.07 0.73 0.41 0.02
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after 8 week administration of Lactobacillus casei [19]. A 
recent meta-analysis by Khalesi et al. from 9 clinical tri-
als concluded that probiotic administration may mod-
estly improve blood pressure, and the potency maybe 
enhanced if multiple species and strains are taken for 
more than 8 weeks [20].
Despite several trials conducted in the T2DM popula-
tion, there is still lack in uniformity of findings and this 
can be due to discrepancies in sample size, duration of 
treatment, different inclusion criteria and type of analy-
ses done. A major potential source of conflicting results 
from different studies however maybe from the omission 
of strain-specific information from past observations. 
Studies have shown that effects of probiotics are often 
species-, or strain/strains-specific [21, 22]. Hence, infor-
mation on strain-specific mechanisms for the probiot-
ics used are essential. In the present study, the rationale 
for choosing the multiple-strain probiotics for the clini-
cal trial were based on a series of in  vitro experiments 
performed on the probiotic strains’ ability to strengthen 
the epithelial barrier, which, as previously hypothesized, 
is necessary to reduce circulating endotoxin, the pri-
mary endpoint. More specifically, the mechanisms found 
among these strains include (a) in vitro strengthening of 
the epithelial barrier after a pathogenic bacteria stressor 
(B. lactis W52, L. casei W56 and Lc. Lactis W58) and/or 
after an inflammatory stressor (B. bifidum W23, L. acido-
philus W37, L. brevis W63, L. casei W56 and Lc. Lactis 
W19), (b) inhibition of mast cell activation (B. bifidum 
W23, B. lactis W52, L. casei W56 and L. salivarius W24), 
(c) stimulation of anti-inflammatory cytokines (all strains 
except L. salivarius and Lc. Lactis W19) and (d) decreas-
ing lipopolysaccharide load (B. bifidum W23, L. acido-
philus W37 and Lc. Lactis W19) [23].
The authors acknowledge several limitations of this 
study. Gut microbiome analysis was not measured, 
therefore, successful colonization of these strains in the 
intestinal tract cannot be confirmed. Dietary intake and 
physical activity of all participants were also not moni-
tored and this could explain beneficial changes in the pla-
cebo group. Despite randomization and blinding, there 
were still significant differences between placebo and 
probiotics group at baseline. While this was addressed 
by adjusting analyses for baseline differences, the addi-
tional adjustments of covariates made it more difficult to 
elicit the desired treatment effect because of the added 
statistical stringency to the cohort. This is worth high-
lighting because the probiotics group made a more sub-
stantial improvement and hence the disparity with the 
placebo. The study’s strengths include it’s randomized, 
double-blind, placebo-controlled design and well defined 
cohort. To the best of our knowledge this is also the first 
trial on probiotic supplementation in the Arabic T2DM 
population. This is important since the gut microbiome, 
although mostly populated by Firmicutes and Bacteroi-
detes is highly affected not only by the health status of 
the individual, but more so by geography and ethnicity 
[24]. Despite the large dropout rate from participants, 
the study remained sufficiently powered and adequately 
blinded.
Conclusions
In summary, a 12-week, multi-strain probiotic sup-
plementation in medication naïve T2DM individuals 
resulted in no significant changes in circulating endo-
toxin levels but has been beneficial in terms of improved 
HOMA-IR and modest reduction in abdominal adiposity. 
A larger cohort and a longer duration of treatment may 
be necessary to investigate if probiotic supplementation 
can be protective against diabetic complications.
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